Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...
The firm expects its lead CAR T-cell therapy TPST-2003 to begin a Phase IIb registrational trial by the end of this year.
The FDA has cleared the company's investigational new drug application seeking to begin the Phase I/II FUNCTION-DMD trial.
The agency approved the Keytruda-based regimen after reviewing data from the KEYNOTE-B96 trial, in which Agilent's PD-L1 IHC 22C3 PharmDx test was used to stratify patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results